I25 Stock Overview A digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
iRhythm Technologies, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for iRhythm Technologies Historical stock prices Current Share Price US$103.00 52 Week High US$113.00 52 Week Low US$51.00 Beta 1.26 1 Month Change 21.89% 3 Month Change 50.37% 1 Year Change -7.21% 3 Year Change -2.83% 5 Year Change 27.16% Change since IPO 339.03%
Recent News & Updates
iRhythm Technologies, Inc. Announces Mojdeh Poul Decides to Not Seek Re-Election to the Board of Directors Jan 30 Irhythm Technologies, Inc. Provides Earnings Guidance for Full Year 2025
President recently sold €1.1m worth of stock Nov 07
Third quarter 2024 earnings released: US$1.48 loss per share (vs US$0.89 loss in 3Q 2023) Nov 01
iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifications to Its Zio® AT Device Oct 31
iRhythm Technologies, Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 17 See more updates
iRhythm Technologies, Inc. Announces Mojdeh Poul Decides to Not Seek Re-Election to the Board of Directors Jan 30 Irhythm Technologies, Inc. Provides Earnings Guidance for Full Year 2025
President recently sold €1.1m worth of stock Nov 07
Third quarter 2024 earnings released: US$1.48 loss per share (vs US$0.89 loss in 3Q 2023) Nov 01
iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifications to Its Zio® AT Device Oct 31
iRhythm Technologies, Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 17
New minor risk - Profitability Sep 25
iRhythm Technologies, Inc. Reaffirms Earnings Guidance for the Year 2024 Sep 04
iRhythm Technologies, Inc. Announces Results of GUARD-AF Trial Sep 02
New minor risk - Share price stability Aug 05
Second quarter 2024 earnings released: US$0.65 loss per share (vs US$0.61 loss in 2Q 2023) Aug 02 Irhythm Technologies, Inc. Provides Earnings Guidance for the Year 2024
iRhythm Technologies, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 19
iRhythm Technologies, Inc. Achieves Significant Operational Milestone with Launch of Initial Phase of Manufacturing Automation Jun 19
Forecast to breakeven in 2026 May 03
iRhythm Technologies, Inc. Revises Earnings Guidance for the Year 2024 May 03
iRhythm Technologies, Inc. to Report Q1, 2024 Results on May 02, 2024 Apr 20
New minor risk - Profitability Apr 16
iRhythm Technologies, Inc., Annual General Meeting, May 29, 2024 Apr 12
New minor risk - Shareholder dilution Apr 11
President recently sold €2.8m worth of stock Mar 04
Forecast to breakeven in 2026 Feb 26
Full year 2023 earnings released: US$4.04 loss per share (vs US$3.88 loss in FY 2022) Feb 23
iRhythm Technologies, Inc. Provides Earnings Guidance for the Year 2024 Feb 23
iRhythm Technologies, Inc. to Report Q4, 2023 Results on Feb 22, 2024 Feb 09
Bernstein Litowitz Berger & Grossmann LLP Files Securities Class Action Lawsuit Against iRhythm Technologies, Inc Feb 07 iRhythm Technologies, Inc. Revises Revenue Guidance for the Year 2024 Jan 08
Insider recently sold €680k worth of stock Jan 05
iRhythm , Inc. Announces Results from the Cardiac Ambulatory Monitor EvaLuation of Outcomes and Time to Events Jan 05
iRhythm Technologies, Inc. Provides Revenue Guidance for the Full Year 2023 Nov 03
Third quarter 2023 earnings released: US$0.89 loss per share (vs US$0.71 loss in 3Q 2022) Nov 03
iRhythm Technologies, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 20
iRhythm Launches Next Generation Zio Monitor and Enhanced Zio Service: Its Smallest, Lightest and Thinnest Cardiac Monitor Sep 27
Second quarter 2023 earnings released: US$0.61 loss per share (vs US$0.80 loss in 2Q 2022) Aug 04 iRhythm Technologies, Inc. Provides Earnings Guidance for the Full Year 2023
iRhythm Technologies, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 23
Executive VP & Chief Risk Officer recently sold €115k worth of stock Jun 07
iRhythm Technologies, Inc. Announces Director Appointments Jun 07
iRhythm Technologies, Inc. Provides Earnings Guidance for the Year 2023 May 06
First quarter 2023 earnings released: US$1.29 loss per share (vs US$1.71 loss in 1Q 2022) May 05
Now 23% undervalued Mar 31
COO & Secretary recently sold €391k worth of stock Mar 05
Full year 2022 earnings released: US$3.88 loss per share (vs US$3.46 loss in FY 2021) Feb 24
iRhythm Technologies, Inc. to Report Q4, 2022 Results on Feb 23, 2023 Feb 10
Chief Legal Counsel recently sold €174k worth of stock Dec 07
President recently sold €1.6m worth of stock Nov 05
Now 20% undervalued after recent price drop Nov 04
Third quarter 2022 earnings released: US$0.71 loss per share (vs US$0.81 loss in 3Q 2021) Nov 03
iRhythm Technologies, Inc. Revises Earnings Guidance for the Year 2022 Nov 02
iRhythm Technologies, Inc. to Report Q3, 2022 Results on Nov 01, 2022 Oct 21
iRhythm Technologies, Inc. Reiterates Revenue Guidance for the Year 2022 Sep 23
iRhythm Technologies, Inc. Provides Revenue Guidance for the Full Year of 2022 Aug 06
Second quarter 2022 earnings released: US$0.80 loss per share (vs US$0.59 loss in 2Q 2021) Aug 05 iRhythm Technologies, Inc. Appoints Brice Bobzien as Chief Financial Officer, Effective August 8, 2022
iRhythm Gains FDA Clearance for its Clinically Integrated ZEUS System Jul 23 iRhythm Technologies, Inc. Announces Management Changes
Executive Vice President of Strategy recently sold €152k worth of stock Jul 09
Independent Director recently sold €54k worth of stock Jun 17
First quarter 2022 earnings released: US$1.71 loss per share (vs US$0.95 loss in 1Q 2021) May 07
iRhythm Technologies, Inc. Provides Earnings Guidance for the Fiscal Year 2022 May 06 iRhythm Technologies, Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 22
iRhythm Technologies, Inc., Annual General Meeting, May 26, 2022 Apr 15
iRhythm Technologies, Inc. Announces the Results of Three Clinical Research Studies Presented At the American College of Cardiology’s 71 Annual Scientific Session & Expo Apr 04
Consultant & Director recently sold €828k worth of stock Mar 09
iRhythm Technologies, Inc. Announces the Results of the KP-Rhythm2 Study Mar 01
iRhythm Technologies, Inc. Provides Revenue Guidance for the Full Year 2022 Feb 24
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
COO, CFO & Secretary recently sold €490k worth of stock Feb 23
iRhythm Technologies, Inc. to Report Q4, 2021 Results on Feb 23, 2022 Feb 10
Insufficient new directors Jan 12
Third quarter 2021 earnings released: US$0.81 loss per share (vs US$0.17 loss in 3Q 2020) Nov 06
iRhythm Technologies, Inc. Provides Revenue Guidance for the Full Year of 2021 Aug 08
Second quarter 2021 earnings released: US$0.59 loss per share (vs US$0.75 loss in 2Q 2020) Aug 06
iRhythm Technologies, Inc.(NasdaqGS:IRTC) dropped from Russell 2000 Growth-Defensive Index Jun 28
President, CEO & Director Michael Coyle has left the company Jun 05
iRhythm Technologies Continues to Fuel Innovation in Cardiac Monitoring and Unveils Two FDA Clearances for Superior Patient Care May 25
iRhythm Technologies, Inc. Provides Earnings Guidance for the First Quarter of 2021 May 07
First quarter 2021 earnings released: US$0.95 loss per share (vs US$0.34 loss in 1Q 2020) May 07
Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against iRhythm Technologies, Inc Mar 19
New 90-day low: €120 Mar 05
Full year 2020 earnings released: US$1.58 loss per share (vs US$2.16 loss in FY 2019) Feb 27
Revenue beats expectations Feb 27
Study Published in Jama Cardiology Finds Zio by iRhythm Proactively Identifies Atrial Fibrillation, Increases Detection Tenfold Feb 25
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against iRhythm Technologies, Inc Feb 17
Bragar Eagel & Squire, P.C. Reminds Investors that Class Action Lawsuits Have Been Filed Against 9F Inc., Astrazeneca, Irhythm Technologies, and Tyson Foods, Inc Feb 13 Kessler Topaz Meltzer & Check, LLP Announces A Securities Fraud Class Action Filed Against Irhythm Technologies, Inc Rosen Law Firm Encourages iRhythm Technologies, Inc. Investors with Large Losses to Secure Counsel Before Important Deadline - IRTC Shareholder Returns I25 DE Medical Equipment DE Market 7D 1.0% 2.9% 1.9% 1Y -7.2% -1.0% 15.1%
See full shareholder returns
Return vs Market: I25 underperformed the German Market which returned 15.1% over the past year.
Price Volatility Is I25's price volatile compared to industry and market? I25 volatility I25 Average Weekly Movement 8.5% Medical Equipment Industry Average Movement 6.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: I25's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: I25's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period.
Show more iRhythm Technologies, Inc. Fundamentals Summary How do iRhythm Technologies's earnings and revenue compare to its market cap? I25 fundamental statistics Market cap €3.29b Earnings (TTM ) -€145.34m Revenue (TTM ) €540.26m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) I25 income statement (TTM ) Revenue US$560.03m Cost of Revenue US$180.14m Gross Profit US$379.89m Other Expenses US$530.54m Earnings -US$150.65m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -4.81 Gross Margin 67.83% Net Profit Margin -26.90% Debt/Equity Ratio 899.9%
How did I25 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/02 12:01 End of Day Share Price 2025/01/31 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources iRhythm Technologies, Inc. is covered by 21 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Michael Polark Baird David Rescott Baird Joanne Wuensch BMO Capital Markets Equity Research
Show 18 more analysts 
